ContraBand™: Safety & Feasibility Study (RM-20-01)

Main Inclusion Criteria: * Age is 18 - 85 years old * Chronic heart failure (\> 3 months) * Symptomatic left heart failure Stage C (NYHA Class III-IVa) or Class II with documented prior history of Class III-IVa heart failure. * LVEF 20 - 40% * Receiving optimally tolerated GDMT for at least 3 (three) months as referred in the 2021 ESC Guidelines for the optimal recommended pharmacological treatment indicated in patients with (NYHA class II-IV) heart failure with reduced ejection fraction (LVEF\< 40%). * If indicated according to the 2021 ESC Guidelines: Subject has an implantable cardioverter-defibrillator (ICD) for at least 1 month prior to screening. or subject is on cardiac resynchronization therapy (CRT)/pacemaker for at least 3 months prior to screening. * Able to complete six-minute walk test (6MWT) with distance between 100 meters and 400 meters. Main Exclusion Criteria: * Serum NT-proBNP \<300 pg/mL * Significant RV dysfunction with TAPSE \< 15 mm * Moderate to severe pulmonary hypertension (Pulmonary vascular resistance PVR ≥ 4.0 WU and PAPi \< 1.0 by RHC) * Anatomical pathology or constraints preventing appropriate access/implant of ContraBand™ * Restrictive Cardiomyopathy or myocarditis * Any severe valve disease (Grade 3-4) and/or tricuspid regurgitation ≥ 2+ (in a scale of 5) * Hemodynamic instability: Hypotension (systolic pressure \<90 mmHg) or requirement for inotropic support or mechanical hemodynamic support * Active bacterial endocarditis or previous history of SBE (Subacute bacterial endocarditis) * Any planned cardiac surgery or interventions within the next six (6) months * Need for coronary artery revascularization * Myocardial infarction or any percutaneous cardiovascular intervention within 1 month * Cardiovascular surgery, or carotid surgery within 3 months * Acute kidney insufficiency and/or end stage renal disease requiring chronic dialysis (eGFR \< 30) * Leukopenia (WBC \< 4000 cells/μL), anemia (Hgb \< 9 g/dL), thrombocytopenia (platelets \< 150,000 cells/μL) or any known blood clotting disorder * History of systemic or pulmonary thromboembolism within 12 months prior to Baseline visit; incidental small peripheral pulmonary emboli deemed clinically insignificant by the investigator are not considered exclusionary * Previous history of cardiogenic shock (unrelated to myocardial infraction) * Stroke, transient ischemic attack (TIA) or deep vein thrombosis (DVT) within 6 months of screening